Sign in
TerminatedNo phase

MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender Women

Key facts

Who runs it
Public Health Foundation Enterprises, Inc.
Where
San Francisco, United StatesSee the site
Trial code
Status
Terminated
People taking part
2 people enrolled
Started
18 Mar 2023
Ended
21 Mar 2025
Type of study
Interventional, 2 groups
Treatments tested
  • MyPrEP Plus Package
  • Standard of Care (SOC)
Record updated
28 August 2025
Why it stopped
Recruitment was halted prematurely as a result of the termination of the grant by the NIH.

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Can take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Are age 18 or older
  • Identify as a transgender woman or woman and was assigned male sex at birth
  • Are not currently on PrEP in the last three months and interested in learning more about PrEP
  • Able to successfully send and receive text messages
  • HIV negative by self-report
  • Are able to speak, read and write in English or Spanish
  • Report any of the following in the last 12 months:; Having anal or vaginal sex with a person assigned male at birth; Exchange of sex for money, goods, or services; Received a diagnosis of a sexually transmitted infection; Sharing injection equipment
  • Are able and willing to provide written informed consent and participate for the duration of the study

Who cannot take part

  • In a mutually monogamous sexual relationship with an HIV-negative partner for the past 12 months
  • Of any medical, psychiatric, or social condition that in the opinion of the investigator would preclude participation or their ability to remain in the trial
  • Study site staff member

Where in United States

  • Bridge HIV, San Francisco Department of Public HealthSan Francisco, United States

About the trial

What the trial wants to find out

The primary goal of this randomized controlled trial is to learn if a decision support tool called MyPrEP Plus can help transgender women make decisions about taking pre-exposure prophylaxis (PrEP) for HIV prevention.

The 2 groups in the trial

  • Experimental Conditon: MyPrEP PlusTreatment being tested

    The intervention administered in the experimental condition includes PrEP decisional and adherence support with the MyPrEP Plus package.

    Treatment: MyPrEP Plus Package

  • Control Condition: Standard of CareOther group

    Participants randomized to the control condition will receive PrEP support through the standard of care.

    Treatment: Standard of Care (SOC)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
28 August 2025